About this trial
Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.
This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.
The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.
Eligibility criteria
Qualifiers
Undergoing diagnostic evaluation for suspected lung cancer
Spirometry showing obstructive airflow limitation (FEV₁/FVC < 75 % or FEV₁ < 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation
Disqualifiers
Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry
Pregnant or breastfeeding women
Trial design
Treatments tested in this trial
- Tailored COPD consultations
Treatment groups
Sponsors and collaborators
Ditte Krag-Hansen
Lead sponsor
Region of Southern Denmark
Sponsor institution
AstraZeneca
Collaborator
Sygehus Lillebaelt
Collaborator